RecruitingObesity or Overweight
A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity
Eligible age
18+ yrs
Accepts
All genders
Locations
3 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study will evaluate the efficacy and safety of petrelintide compared with placebo, in conjunction with a reduced-calorie diet and increased physical activity, for weight management in participants living with overweight or obesity, at least one weight-related comorbidity, and without Type 2 Diabetes (T2D).
Sponsor: Hoffmann-La Roche
You may qualify if…
- ✓ Participants with BMI ≥ 30 kg/m² or BMI ≥ 27 kg/m² with at least one weight-related comorbidity
- ✓ History of at least one self-reported unsuccessful dietary effort to lose body weight
You may not qualify if…
- ✕ HbA1c ≥ 48 mmol/mol (6.5%), measured by the central laboratory at screening
- ✕ Known history of Type 1 or Type 2 diabetes mellitus
- ✕ Current or previous treatment with petrelintide or any other amylin analog
Where it's recruiting
Source: ClinicalTrials.gov · NCT07843498 · last updated 2026-10-07